Medical Patent News

RSS

Skinvisible granted Japanese patent for Invisicare

Skinvisible, Inc. has announced that it has been granted a comprehensive patent in Japan for Invisicare, a product-enhancing polymer delivery system for topical dermatology products. The patent protects Invisicare in the areas of 'Topical Composition,' 'Topical Composition Precursor,' and 'Methods for Manufacturing and Using.'

11 Mar 2009

Patented inventions double at University at Buffalo

An antibody with the potential to stop breast cancer in its path. A nanoparticle that can address a side effect of the treatment that hemophiliacs cannot live without. A "quantum dot" with the potential to treat cancer or harvest the power of the sun. An air purifier that kills the world's nastiest toxins.

5 Mar 2009

Cordex Pharma files ATPace formulation patent

Cordex Pharma, Inc. has announced today that it has filed a formulation patent covering its lead product, ATPace.

4 Mar 2009

VIA Pharmaceuticals awarded new patent on lead compound VIA-2291

VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.

25 Feb 2009

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss.

24 Feb 2009

Bone Biologics issued U.S. patent for recombinant protein process

Bone Biologics Inc. has announced that it has received a US Patent Office Notice of Allowance of patent claims which protect a method of production for the UCB-1 (NELL-1) recombinant protein that Bone Biologics uses in the bone repair/regeneration technology in its lead product.

24 Feb 2009

Stromedix awarded U.S. patent for antibody-based therapeutics

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that the U.S. Patent Office has granted patent number US 7,465,449, which broadly covers monoclonal antibodies to integrin ávâ6, including compositions related to its lead product, STX-100.

23 Jan 2009

Aribex awarded patents for NOMAD handheld X-ray system

Aribex, Inc. has announced that it has been allowed a second U.S. patent for its NOMAD Handheld X-ray System.

19 Jan 2009

HPS files world patent for mood-enhancing compound from sea coral

Human Pheromone Sciences, Inc. has announced that it has filed a Comprehensive Patent Application with the International Bureau of the World Patent Office for the use of its innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

19 Jan 2009

Advaxis wins European patent case involving Lovaxin-C vaccine

The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp.

15 Jan 2009

Oncolytics Biotech issued new U.S. patent

Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled "Reovirus for the Treatment of Neoplasia." The patent includes claims to pharmaceutical compositions containing reovirus.

13 Jan 2009

Dey L.P. issued new U.S. patents for Perforomist inhalation solution

Mylan Inc. has announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company's Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.

12 Jan 2009

Bavarian Nordic's patent infringement suit against Oxford BioMedica

Bavarian Nordic owns several United States patents relating to an attenuated strain of the company's core technology, MVA-BN(R), which is the basis for its smallpox vaccine, IMVAMUNE(R).

12 Jan 2009

U.S. patent for NanoLantern diagnostic technology

The University of Rochester Medical Center (URMC) has received a U.S. patent for a diagnostic technology that can rapidly and accurately screen for organisms such as bacteria and other infectious agents.

9 Jan 2009

Genta Incorporated issued two key U.S. patents for gallium products franchise

Genta Incorporated has announced that two new patents related to the Company's franchise in gallium-containing products have issued in the United States.

8 Jan 2009

SpectraScience awarded U.S. patent for methods and apparatus for evaluating image focus

SpectraScience, Inc. has announced that it has been awarded U.S. Patent number 7,469,160 for its methods and apparatus for evaluating image focus.

6 Jan 2009

PDL BioPharma and Alexion Pharmaceuticals resolve patent dispute

PDL BioPharma, Inc. and Alexion Pharmaceuticals, Inc. today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris (eculizumab) and PDL's patents known as the Queen et al. patents.

5 Jan 2009

Human Pheromone Sciences files patent for mood enhancing compound derived from sea coral

Human Pheromone Sciences, Inc. has announced that it has filed a Comprehensive Patent Application with the U.S. Patent and Trademark Office for the use of an innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

17 Dec 2008

Nutraceutix issued Australian patent

The Australian Patent Office has issued Nutraceutix, Inc. a patent for BIO-tract.

16 Dec 2008

Epeius Biotechnologies awarded European patents for targeted genetic anti-cancer medicine

Epeius Biotechnologies Corporation has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body.

16 Dec 2008